Testing new HIV treatments for children and teens in Africa
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial compares new HIV medicines to help children and teens who have HIV and are either starting treatment or whose current treatment isn't working. The goal is to find better ways to control the virus and keep kids healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 4 weeks and 14 years old and weighs at least 3 kilograms, but less than 30 kilograms.
- Your child must have a confirmed HIV infection.
- Your child is either starting HIV treatment for the first time, or has been on a dolutegravir-based HIV treatment for at least 6 months but the virus is still not controlled.
- Your child can attend follow-up visits for at least 48 weeks.
- Your child does not have severe liver, kidney, or other life-threatening health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This study tests whether a combination of special antibodies (bNAbs) can help control HIV without daily medication. It involves several steps and is for children who are already doing well on ART.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.